Research update covering mid-May to early June 2026
Key points
- New research suggests Aspergillus infection may develop during tuberculosis treatment, rather than only years afterwards.
- A large cystic fibrosis registry study has improved understanding of who is most at risk of developing Allergic Bronchopulmonary Aspergillosis (ABPA).
- A case report highlights that ABPA can occasionally cause severe mucus plugging and even lung collapse.
- New studies continue to improve testing for Chronic Pulmonary Aspergillosis (CPA), including Aspergillus antibody tests.
- Several papers evaluated newer diagnostic tools including PCR, galactomannan, lateral flow testing and metagenomic sequencing.
- Researchers are increasingly exploring treatments that support the immune system, rather than only targeting the fungus directly.
Introduction
The last two weeks have seen a wide range of new aspergillosis research covering diagnosis, risk factors, immune responses and future treatment possibilities.
A clear theme emerging from recent studies is the move towards earlier diagnosis and more personalised approaches to care. Researchers are also increasingly investigating how the immune system interacts with Aspergillus and whether improving immune function could become part of future treatment strategies.
Can Aspergillus infection begin during tuberculosis treatment?
One of the most interesting studies came from Peru, where researchers investigated Aspergillus infection among patients receiving treatment for pulmonary tuberculosis.
Traditionally, doctors have believed that Chronic Pulmonary Aspergillosis often develops months or years after tuberculosis causes lung damage. However, this study raises the possibility that Aspergillus infection may sometimes emerge during active tuberculosis treatment itself.
This finding is important because CPA is a recognised complication of tuberculosis worldwide. If future studies confirm these findings, clinicians may need to monitor some tuberculosis patients more closely for signs of fungal infection much earlier than previously thought.
Large registry study improves understanding of ABPA risk
Researchers in Turkey analysed data from a national cystic fibrosis registry to examine how often Allergic Bronchopulmonary Aspergillosis develops and which patients are most likely to be affected.
Large registry studies are valuable because they include information from many patients over extended periods of time. This allows researchers to identify patterns that smaller studies may miss.
The study helps improve understanding of how frequently ABPA develops, which patients appear to be at greatest risk, and which factors may be associated with disease development.
ABPA can sometimes cause severe airway blockage
A striking case report described a patient whose ABPA presented with complete collapse of one lung and respiratory failure.
Although uncommon, this case highlights an important aspect of ABPA that many patients already recognise from personal experience: mucus plugging can sometimes become severe.
In ABPA, inflammation causes excessive mucus production within the airways. In some cases, thick mucus plugs can partially or completely block sections of the lung.
Improved blood tests for Chronic Pulmonary Aspergillosis
Researchers have reported new work aimed at improving Aspergillus antibody testing for Chronic Pulmonary Aspergillosis.
Diagnosis of CPA often depends on a combination of symptoms, CT scan findings, evidence of Aspergillus infection and Aspergillus antibody testing. Current blood tests are useful but not perfect. Improving their accuracy could help reduce missed diagnoses and improve confidence when diagnosing CPA.
New diagnostic technologies continue to advance
PCR testing
A clinical evaluation of a commercial Aspergillus fumigatus PCR test in patients with haematological malignancies examined how accurately the test identifies invasive pulmonary aspergillosis.
Metagenomic sequencing
Researchers also published a systematic review and meta-analysis examining metagenomic next-generation sequencing for invasive pulmonary aspergillosis.
This technology analyses genetic material from all organisms present in a sample rather than looking for a single pathogen. Although currently expensive and not widely available, it may play an increasing role in future fungal diagnostics.
Lateral flow testing
Another study evaluated a lateral flow device designed to detect Aspergillus antigens. These tests could eventually help make fungal diagnostics faster and more accessible.
New insights into galactomannan testing
Researchers investigated whether comparing galactomannan levels in bronchial washing samples and blood samples could improve diagnosis of pulmonary aspergillosis.
Galactomannan is one of the most widely used fungal biomarkers. Refining how it is interpreted may improve diagnostic accuracy and help clinicians distinguish between infection and other conditions.
Could future treatment involve strengthening the immune system?
Some of the most exciting research focused on immune-based therapies. Rather than directly targeting Aspergillus, researchers are exploring ways to improve the body’s ability to fight infection.
Anti-PD-1 and interferon-gamma
A study examined emerging evidence for anti-PD-1 therapy and interferon-gamma as adjunctive immunotherapy in invasive mould infections.
These approaches aim to reverse immune exhaustion and improve natural antifungal responses. They remain experimental, but they represent an important future direction.
Enhancing neutrophil function
Another study examined how G-CSF may improve neutrophil activity during Aspergillus fumigatus infection.
Neutrophils are among the body’s most important immune cells for controlling Aspergillus. Improving their function could potentially help patients whose immune systems struggle to clear fungal infections.
Therapeutic drug monitoring remains important
A case report highlighted how voriconazole blood levels changed significantly as inflammation improved during treatment.
This reinforces an important principle already recognised by specialist centres: antifungal drug levels can change over time, and therapeutic drug monitoring remains an important part of safe and effective treatment.
What does this mean for patients?
Several themes stand out from this fortnight’s research.
First, researchers continue to focus heavily on earlier diagnosis. Better blood tests, improved PCR methods, lateral flow devices and sequencing technologies all aim to identify aspergillosis more accurately and more quickly.
Second, there is growing interest in understanding which patients are most at risk of developing aspergillosis. This may eventually lead to more personalised monitoring and earlier intervention.
Finally, scientists are increasingly exploring immune-based therapies. While antifungal drugs remain the foundation of treatment, future care may involve helping the immune system fight fungal infection more effectively.
When should patients seek medical advice?
Patients should seek medical advice if they experience:
- worsening breathlessness
- persistent cough
- new coughing up of blood
- unexplained weight loss
- increasing fatigue
- persistent chest symptoms despite treatment
Patients with previous tuberculosis, bronchiectasis, severe asthma or cystic fibrosis should be particularly aware of symptoms that do not improve as expected.
References
- Bigot J et al. Aspergillus serology for chronic pulmonary aspergillosis diagnosis. Journal of Clinical Microbiology, 2026. PubMed
- Demir HI et al. Yearly distribution and risk factors for ABPA in the Turkish cystic fibrosis registry. Chronic Illness, 2026. PubMed
- Gibert C et al. Clinical evaluation of a commercial Aspergillus fumigatus PCR assay. Journal of Infectious Diseases, 2026. PubMed
- Lv H et al. Diagnostic accuracy of metagenomic next-generation sequencing for invasive pulmonary aspergillosis. International Journal of Infectious Diseases, 2026. PubMed
- Madden AE et al. Prevalence and clinical implications of Aspergillus infection among tuberculosis patients in Peru. Journal of Infection, 2026. PubMed
- Medina A et al. Real-life performance of AspLFD in lower respiratory tract and serum specimens. Diagnostic Microbiology and Infectious Disease, 2026. PubMed
- Rai DK et al. ABPA presenting as unilateral lung collapse with respiratory failure. BMJ Case Reports, 2026. PubMed
- Serris A et al. Anti-PD-1 and interferon-gamma as adjunctive immunotherapy in invasive mould infections. mBio, 2026. PubMed
- Toychiev A et al. Vitamin D status and immune response in pulmonary tuberculosis patients with CPA. Tuberculosis, 2026. PubMed
- Yamaguchi K et al. Bronchial washing-to-serum galactomannan antigen ratio for pulmonary aspergillosis diagnosis. Journal of Microbiological Methods, 2026. PubMed
Last reviewed: 1 June 2026
“`
Latest News posts
News archive